tbuckley/cabot-search huggingface dataset:
Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine
Authors: Jessica Liegel, Manoj Bhasin, German A. Pihan, Dina Stroopinsky, Beena Thomas, Shreya Sindhu, Haider Ghiasuddin, Emma Logan, Adam Morin, Marzia Capelletti, Shira Orr, Myrna Nahas, Matthew Weinstock, Maryam Rahimian, Lina Bisharat, Shufen Meng, Richard M. Stone, Donald Kufe, David E. Avigan, Jacalyn Rosenblatt
Journal: Blood (2019)
REDUCE-IT USA
Authors: Deepak L. Bhatt, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Ph. Gabriel Steg, Steven B. Ketchum, Ralph T. Doyle, Rebecca A. Juliano, Lixia Jiao, Craig Granowitz, Jean-Claude Tardif, Brian Olshansky, Mina K. Chung, C. Michael Gibson, Robert P. Giugliano, Matthew J. Budoff, Christie M. Ballantyne
Journal: Circulation (2019)

Some trials have found that patients from the United States derive less benefit than patients enrolled outside the United States. This prespecified REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial) subgroup analysis was conducted to determine the degree of benefit of icosapent ethyl in the United States.
PBX1 Co-Operates with FOXM1 to Regulate Myeloma Cell Proliferation and to Define an Ultra High-Risk chr1q Gain Myeloma Patient Subgroup
Authors: Nikolaos Trasanidis, Alexia Katsarou, Bien Bergonia, Keren Keren, Ioannis V. Kostopoulos, Kanagaraju Ponnusamy, Reema Paudel, Xiaolin Xiao, Holger W Auner, Irene Roberts, Kikkeri Naresh, Aristeidis Chaidos, Luca Magnani, Valentina S Caputo, Anastasios Karadimitris
Journal: Blood (2019)
Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response
Authors: Karen W.L. Yee, Gail J. Roboz, Casey L. O'Connell, Elizabeth A. Griffiths, Raoul Tibes, Katherine J. Walsh, Wendy Stock, Guillermo Garcia-Manero, Michael R. Savona, Farhad Ravandi, Naval G. Daver, Elias Jabbour, Todd L. Rosenblat, Jean-Pierre Issa, Xiang Yao Su, Mohammad Azab, Hagop M. Kantarjian
Journal: Blood (2019)
Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial
Authors: Peter J Goadsby, Soma Sahai-Srivastava, Eric J Kezirian, Anne H Calhoun, David C Matthews, Peter J McAllister, Peter D Costantino, Deborah I Friedman, John R Zuniga, Laszlo L Mechtler, Saurin R Popat, Ali R Rezai, David W Dodick
Journal: The Lancet Neurology (2019)
Applications of Higher Order Statistics in Electroencephalography Signal Processing: A Comprehensive Survey
Authors: Seyed Alireza Khoshnevis, Ravi Sankar
Journal: IEEE Reviews in Biomedical Engineering (2019)

Electroencephalography (EEG) is a noninvasive electrophysiological monitoring technique that records the electrical activities of the brain from the scalp using electrodes. EEG is not only an essential tool for diagnosing diseases and disorders affecting the brain, but also helps us to achieve a better understanding of brain's activities and structures. EEG recordings are weak, nonlinear, and nonstationary signals that contain various noise and artifacts. Therefore, for analyzing them, advanced signal processing techniques are required. Second order statistical features are usually sufficient for analyzing most basic signals. However, higher order statistical features possess characteristics that are missing in the second order; characteristics that can be highly beneficial for analysis of more complex signals, such as EEG. The primary goal of this article is to provide a comprehensive survey of the applications of higher order statistics or spectra (HOS) in EEG signal processing. Therefore, we start the survey with a summary of previous studies in EEG analysis followed by a brief mathematical description of HOS. Then, HOS related features and their applications in EEG analysis are presented. These applications are then grouped into three categories, each of which are further explored thoroughly with examples of prior studies. Finally, we provide some specific recommendations based on the literature survey and discuss possible future directions of this field.
Vitiligo under anti–programmed cell death-1 therapy is associated with increased survival in melanoma patients
Authors: Charlée Nardin, Anne Jeand'heur, Kévin Bouiller, Marie Blanche Valnet-Rabier, Flora Dresco, Julie Castagna, Adrien Mareschal, Clémentine Carlet, Virginie Nerich, Samuel Limat, Eve Puzenat, François Aubin
Journal: Journal of the American Academy of Dermatology (2019)
Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients
Authors: Tracy Murphy, Stanley W.K. Ng, Tong Zhang, Ian King, Andrea Arruda, Jaime O. Claudio, Narmin Ibrahimova, Fiona Ferrera, Chantal Rockwell, Zhibin Lu, Natalie Stickle, Carl Virtanen, Brian Leber, Mitchell Sabloff, Mark D. Minden, Tracy L. Stockley, Steven M Chan, Jean C.Y. Wang
Journal: Blood (2019)
ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study
Authors: Patrizia Mondello, Irene Dogliotti, Jan-Paul Bohn, Federica Cavallo, Simone Ferrero, Barbara Botto, Claudio Cerchione, Davide Nappi, Sonya De Lorenzo, Giovanni Martinelli, Dominik Wolf, Giacomo Loseto, Salvatore Cuzzocrea, Wolfgang Willenbacher, Michael Mian
Journal: Blood (2019)
Abstract 15234: Targeted Inhibition of NADPH Oxidase in the Posterior Left Atrium by Nox2 shRNA Decreases Formation of Atrial Fibrillation Substrate in Heart Failure
Authors: Shin Yoo, Gary L Aistrup, Suzanne Browne, Aaron Kunamalla, Brandon Smeltzer, John A Wasserstrom, Jason Ng, David Gordon, Alan Kadish, Bradley Knight, Rod Passman, Jeffrey Goldberger, Rishi Arora
Journal: Circulation (2013)

Introduction: Oxidative stress is thought to play an important role in the pathogenesis of atrial fibrillation (AF). Recent studies indicate that NADPH oxidase (NOX2) is a major source of reactive ...
PD2.03 Exploration of Factors Relating to Immune Response in Patients Treated with Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (NSCLC)
Authors: A.F. Cardona, O. Arrieta, A. Ruiz-Patiño, L. Zatarain Barron, L. Corrales-Rodriguez, C. Martín, F. Barrón, C. Sotelo, J. Rodríguez, L. Ricaurte, H. Freitas, V.C. Cordeiro De Lima, L. Mas, J. Ávila, D. Mayorga, P. Archila, J. Otero, H. Carranza, C. Vargas, R. Rosell
Journal: Journal of Thoracic Oncology (2019)
Low-Dose Methotrexate Could Reduce Severe Early Immune Reactions but Probably Increase Garft Failure in Umbilical Cord Blood Transplantation
Authors: Liu Huilan, Xiaoyu Zhu, Kaidi Song, Xiang Wan, Guangyu Sun, Baolin Tang, Juan Tong, Wen Yao, Xuhan Zhang, Liangquan Geng, Zimin Sun
Journal: Blood (2019)
The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Authors: Kelly S. Chien, Rashmi Kanagal-Shamanna, Kiran Naqvi, Koji Sasaki, Yesid Alvarado, Koichi Takahashi, Tapan M. Kadia, Gautam M. Borthakur, Elias Jabbour, Mark Routbort, Sherry A. Pierce, Kelly Soltysiak, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo
Journal: Blood (2019)
RBTT-04. DGM1 MAY SERVE AS A NOVEL GENETIC BIOMARKER OF RESPONSE TO ENZASTAURIN IN GLIOBLASTOMA
Authors: Nicholas Butowski, Lei Zhang, Hong Sun, Isabel Han, Manoj jivani, Ling Li, Wen Luo
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND No significant progress has been made over the last decade in therapies available for glioblastoma (GBM) with survival remaining poor. Meaningful advances in treating this deadly malignancy may rely on precision medicine. A novel pharmacogenomic biomarker, Denovo Genomic Marker 1 (DGM1), for enzastaurin (enz) in treating lymphoma was discovered. It was evaluated to predict enz response in GBM. METHODS Biomarker discovery was performed by a genome-wide screen using DNA extracted from blood samples of a ph 3 enz lymphoma trial and confirmed in an independent ph 2 lymphoma trial. The biomarker was evaluated for its predictability in GBM using the archived DNA samples from a ph 1/2 enz GBM trial. RESULTS DGM1, a germline polymorphism on chromosome 8, was found to be highly correlated with response to enz in the two lymphoma trials. Using DNA extracted from pts blood of the single-arm ph 1/2 study with newly diagnosed GBM receiving enz added to radiation and temozolomide (tmz), we found median OS for DGM1+ pts treated with enz was 18 mon vs 12.8 mon for DGM1- pts, HR (95% CI) 0.68 (0.25, 1.81), p = 0.12. Pts receiving a mean daily dose of enz ≥ 245 mg had an OS of 19.8 mon vs 14.9 mon for pts receiving a mean daily dose of &lt; 245 mg [HR (95% CI) 0.55 (0.34, 0.90)]. CONCLUSION These data are supportive of DGM1 as a potentially predictive biomarker for enz response in both lymphoma and GBM. There is an ongoing biomarker-driven pivotal study in lymphoma. DGM1 in GBM will be further evaluated in a planned randomized ph 2b study in newly diagnosed GBM with 500 mg/day of enz in combination with tmz.
Combination of mTOR inhibition and paclitaxel as a personalised strategy in the context of MYC-amplified high-grade serous ovarian cancer
Authors: F.C. Martins, D-L Couturier, I. de Santiago, M. Vias, D. Sanders, A. Piskorz, J. Hall, M. Jimenez-Linan, K. Hosking, R. Crawford, J. Brenton
Journal: Annals of Oncology (2019)
Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes
Authors: Michael R. Savona, Pierre Fenaux, Eric Padron, Mrinal M Patnaik, Uwe Platzbecker, Adam Seegmiller, Raphael Itzykson, Guillermo F. Sanz, Valeria Santini, Eric Solary
Journal: Blood (2019)
Oral Contraceptives and Liver Damage
Authors: H. Carlstrom, S. Hoglund
Journal: BMJ (1965)

Oral Contraceptives and Liver Damage SIR,-The nature of the liver damage associated with oral contraceptives is not clear.Histological examination has apparently been performed only in one case,' and a second case is presented here.A previously healthy quadriparous woman of 38 years gave no history of alcohol or gallbladder disease.In autumn 1963 (and also dur- ing the last months of her pregnancies) she ex- perienced generalized itching.Simultaneously she had started ethinyloestradiol 0.05 mg.+ norethisterone acetate 4 mg.daily with regular breaks.No other drugs.In April 1964 episodic
V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia
Authors: Laura Agresta, Maureen M O'Brien, Kana Mizuno, Robin Norris, Erin H. Breese, Christine L Phillips, Karen Burns, Benjamin Mizukawa, Lynn Lee, Adam Lane, Robert B. Lorsbach, Thomas D. Ryan, Pankaj B. Desai, Alexander A. Vinks, H. Leighton Grimes, John P Perentesis, Michael J. Absalon
Journal: Blood (2019)
Leukemia Burden in Peripheral Blood Has Negative Impact on CD19-CART Cell Culture and Its Clinical Efficacy in Patients with Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia
Authors: Biping Deng, Jing Pan, Shuangyou Liu, Yuehui Lin, Zhaoli Liu, Yunlong Chen, Xiaoming Qu, Yu 'e Zhang, Zhongxin Zhang, Xuansha Niu, Ming Ma, Tong Wu, Alex Hong Chang, Chunrong Tong
Journal: Blood (2019)
Prognostic Impact of the Baseline Immunologic Profile in Patients with Aggressive B Non-Hodgkin Lymphomas
Authors: Safaa M. Ramadan, Giusy Ceparano, Alessandro Cignetti, Simona Sammassimo, Vincenzo Bagnardi, Eleonora Pagan, Daniela Gottardi, Stefano Fiori, Rita Passerini, Tommaso Radice, Giuseppe Saglio, Corrado Tarella
Journal: Blood (2019)
Proteomic Discovery: Elevated Neurogranin Levels in Children with Sickle Cell Disease
Authors: Eboni I. Lance, Lisa Faulcon, Zongming Fu, Jun Yang, Donna Whyte, John J. Strouse, Emily Barron-Casella, Kimberly Jones, Jennifer Van Eck, James F. Casella, Allen Everett
Journal: Blood (2019)
EXTH-05. THERAPEUTIC IMPLICATIONS OF TTFIELDS INDUCED DNA DAMAGE AND REPLICATION STRESS IN NOVEL COMBINATIONS FOR CANCER TREATMENT
Authors: Narasimha Kumar Karanam, Lianghao Ding, Asaithamby Aroumougame, Michael Story
Journal: Neuro-Oncology (2019)

Abstract TTFields are low-intensity, intermediate frequency, alternating electric fields which are applied to tumor regions using non-invasive arrays. TTFields is approved for the treatment of glioblastoma and mesothelioma with clinical trials ongoing in other cancer types. The mechanism of action for TTFields includes interference with mitosis, reduced DNA double strand break (DSB) repair capacity and the frank induction of DNA DSBs. The mechanism by which TTFields induces DNA DSBs appears to be through the enhancement of DNA replication stress with continued TTFields exposure. The induction of DNA DSBs appears to be as a result of significantly reduced expression of the DNA replication complex genes MCM6 and MCM10 as well as the Fanconi’s Anemia (FA) pathway genes. TTFields treatment increases the number of RPA foci, decreases nascent DNA length and increases R-loop formation which are markers of DNA replication stress. These results suggest that TTFields-induced replication stress is the underlying mechanism and cellular endogenous source of DNA DSB generation via replication fork collapse. The current study suggests that TTFields exposure causes a conditional vulnerability environment that renders cells more susceptible to chemotherapeutic agents that induce DNA damage and/or cause replication stress. Supporting this is the synergistic cell killing seen with TTFields exposure concomitant with cisplatin, TTFields plus concomitant PARP inhibition with or without subsequent radiation, or radiation given at the completion of a TTFields exposure. Finally, TTFields-induced mitotic aberrations and DNA damage/replication stress events, although intimately linked to one another as one can expose the other, are likely initiated independently of one another as suggested by the gene expression analysis of 47 key mitosis regulator genes. These results establish that enhanced replication stress and reduced DNA repair capacity are also major mechanisms of TTFields effects, effects for which there are therapeutic implications.
Age-Related Bias in Total Step Count Recorded By Wearable Devices—Reply
Authors: I-Min Lee, Eric J. Shiroma
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
PATH-21. CLINICAL UTILITY OF DNA METHYLATION PROFILING FOR DIAGNOSIS OF CHALLENGING CENTRAL NERVOUS SYSTEM TUMORS: THE TORONTO EXPERIENCE
Authors: Shirin Karimi, Jeffrey Zuccato, Yasin Mamatjan, Sheila Mansouri, Suganth Suppiah, Farshad Nassiri, Phedias Diamandis, David Munoz, Kenneth Aldape, Gelareh Zadeh
Journal: Neuro-Oncology (2019)

Abstract The update on the WHO classification of central nervous system (CNS) tumors incorporated molecular signatures for a more accurate diagnosis. Recently, DKFZ has demonstrated the utility of DNA methylation profiling(MP) for molecular classification of CNS tumors. We performed a prospective clinical study over the last three years to evaluate the clinical utility ofDNA MP on FFPE samples of 66 challenging CNS tumor cases using online DKFZ classifier. Eleven samples were excluded due to low tumor DNA content or low calibration(predictive) scores(CS)&lt; 0.3.DNA MP confirmed the original pathology diagnoses in 15(27%)cases. The integrated molecular diagnoses were changed in 38/55(70%) including establishment of a new diagnostic entity, change in molecular signature and subtyping. TheWHO grades were changed in 16(27%) of the tumors; about two-thirds resulted in upgrading. We detected non-canonical IDH mutations in 9 diffuse gliomas and the CNV plots revealed false positive FISH results for 1p/19q co-deletion in two diffuse gliomas. The CNV plots contributed to the final diagnosis in 40(72%) patients. The molecular subtypes of medulloblastoma, ependymoma and glioblastoma subclasses were determined in 36(65%) cases. Seventy-five percent of cases with confirmation of initial diagnosis or change in molecular diagnosis had CS &gt; 0.5, among which 51% had a CS &gt;0.9. The median and range CS of cases with new diagnostic entity and confirmed cases were 0.86(0.37–0.99) and 0.98(0.42–0.99), respectably. Furthermore, we detected higher CS in IDH-mutant gliomas in comparison to glioblastoma IDH-wild type(P=0.04). We also observed lower CS in mesenchymal glioblastoma in comparison to other subclasses. The MGMT promoter methylation was determined in 17/20(85%) glioblastoma cases. While the DKFZ group established CS of 0.9 as a cut-off for matching to methylation classes, our findings suggest lower threshold values in challenging CNS tumor cases. Our experience indicates clinical utility of MP of challenging CNS tumors as a reliable ancillary diagnostic tool in routine neuropathology practice.
ACTR-70. A MULTISITE CLINICAL TRIAL OF SPECTROSCOPIC MRI-GUIDED RADIATION DOSE ESCALATION IN GLIOBLASTOMA PATIENTS
Authors: Eric Mellon, Saumya Gurbani, Karthik Ramesh, Brent Weinberg, Lawrence Kleinberg, Eduard Schreibmann, Peter Barker, Andrew Maudsley, Hyunsuk Shim, Hui-Kuo Shu
Journal: Neuro-Oncology (2019)

Abstract The standard of care for glioblastoma is neurosurgical resection followed by radiation therapy (RT) and temozolomide (TMZ) chemotherapy. Although RT is effective for glioblastoma, attempts to improve survival using RT dose escalation above 60 Gy have been largely unsuccessful. This may be because prior attempts have been targeted to resection cavity or enhancing tumor, which may not accurately predict areas at highest recurrence risk. To overcome the limitations of standard T1 and T2-weighted MRI in predicting tumor recurrence, we have shown that supplementation with 3D high-resolution spectroscopic MRI (sMRI) identifies actively proliferating tumor beyond areas of T1-enhancement by measuring endogenous metabolites and their ratios. Previously, we demonstrated that the choline to N-acetylaspartate ratio (Cho/NAA) best correlates with tumor cellularity in surgically resected tissue (ρ=0.82, p&lt; 0.001) and, most importantly, areas of sMRI metabolic abnormalities predate disease recurrence in those same areas (Cordova et al, Neuro-Oncology 2016). Therefore, we seek to identify whether sMRI can be used by radiation oncologists to choose the optimal regions to target for RT dose escalation. To assess its feasibility and safety, we developed a web-based imaging platform designed specifically to incorporate sMRI into the RT planning clinical workflow and are using it in a multisite sMRI-guided dose escalation trial (NCT03137888; Emory, Johns Hopkins, U. Miami). Recently, we have completed full enrollment including 30 patients treated with sMRI-guided dose escalated RT across three institutions. We have demonstrated successful integration of sMRI into the RT planning workflow, and we have delivered sMRI-guided dose escalated RT plans to glioblastoma patients without severe adverse events to date. Follow-up data will be analyzed for overall and progression-free survival. Based on the feasibility and safety of this technique in the current trial, we plan to assess the efficacy of sMRI-guided dose-escalated RT on patient outcomes in a NCTN clinical trial.
Invincible arrogance--and patients suffer
Authors: J C McDonald
Journal: BMJ (1981)

sprinters lack stamina, but I imagine that no one would question their cardiopulmonary fitness-while in training.I am also worried by the modified physical fitness index, as this fails to take account of the resting pulse rate.Surely a formula based on percentage increase over resting rate at two, five, and 10 minutes would seem more reasonable, since the normal resting pulse rate can vary from the 40s to the 90s at least-or does a naturally slow pulse rate confer a fitness advantage ?Interestingly, Lieutenant-ColonelPearn referred to Zatopek's fitness index of 172; he was a distance runner with a resting pulse rate of about 40 per minute.But I wonder how Zatopek would have fared on the squash court, where explosive bursts of energy are required, or in gymnastics, in which a completely different sort of fitness and body control is demanded, or in the swimming pool.He certainly would have been
Low Numbers of CD27- IgD- 'Double Negative' Senescent B-Cells Early after Reduced Intensity T Cell Depleted Haematopoietic Stem Cell Transplantation Are Predictive of Subsequent Chronic GvHD
Authors: Francesca Kinsella, Harriet Protheroe, Hayden Pearce, Charlotte F Inman, Suzy A Eldershaw, Joanne Croudace, Ben E Abbotts, Jianmin Zuo, Ram K Malladi, Charles Craddock, Paul Moss
Journal: Blood (2019)
Re-evaluation of human BDCA-2+ DC during acute sterile skin inflammation
Authors: Yi-Ling Chen, Tomas Gomes, Clare S. Hardman, Felipe A. Vieira Braga, Danuta Gutowska-Owsiak, Maryam Salimi, Nicki Gray, David A. Duncan, Gary Reynolds, David Johnson, Mariolina Salio, Vincenzo Cerundolo, Jillian L. Barlow, Andrew N.J. McKenzie, Sarah A. Teichmann, Muzlifah Haniffa, Graham Ogg
Journal: The Journal of Experimental Medicine (2019)

Plasmacytoid dendritic cells (pDCs) produce type I interferon (IFN-I) and are traditionally defined as being BDCA-2+CD123+. pDCs are not readily detectable in healthy human skin, but have been suggested to accumulate in wounds. Here, we describe a CD1a-bearing BDCA-2+CD123int DC subset that rapidly infiltrates human skin wounds and comprises a major DC population. Using single-cell RNA sequencing, we show that these cells are largely activated DCs acquiring features compatible with lymph node homing and antigen presentation, but unexpectedly express both BDCA-2 and CD123, potentially mimicking pDCs. Furthermore, a third BDCA-2–expressing population, Axl+Siglec-6+ DCs (ASDC), was also found to infiltrate human skin during wounding. These data demonstrate early skin infiltration of a previously unrecognized CD123intBDCA-2+CD1a+ DC subset during acute sterile inflammation, and prompt a re-evaluation of previously ascribed pDC involvement in skin disease.